Table 1. Clinical and histological evaluation of EAE induced by PLP 139–151 in B10.S mice treated with anti-CD25 Ab or isotype control.

	Clinical disease*			Histopathology†, no. of inflammatory lesions
Treatment	Incidence‡ (%)	Mean day of onset	Mean maximum score	Meninges	Parenchyma	Total
Anti-CD25 Ab	9/32 (28.1)	13.8 ± 1.4	2.2 ± 0.6	44.1 ± 14.0	42.6 ± 17.6	86.9 ± 31.1
Rat IgG control	0/34 (0)	0	0	0	0	0

Numbers are mean ± SEM

^*B10.S mice were treated with anti-CD25 or rat IgG Ab on days 5 and 3 prior to immunization with PLP 139–151 in CFA, and the disease was scored as described in Materials and Methods and compared between the two groups (P = 0.0015)

^†n = 9 for the anti-CD25 Ab group, and n = 27 for the rat IgG control group

^‡Represents the mice that showed both clinical and histological EAE